Intervention not reported
Overall survival (at 36 months) · patients after allogeneic stem cell or bone marrow transplantation
The intervention showed no clear difference in overall survival (at 36 months) (moderate certainty).
1 finding from 1 review
Intervention not reported
Acute GVHD II to IV (90 days) · patients after allogeneic stem cell or bone marrow transplantation
The intervention leads to lower acute GVHD II to IV (90 days) (high certainty).
1 finding from 1 review
Intervention not reported
Overall Chronic GVHD (up to 36 months) · patients after allogeneic stem cell or bone marrow transplantation
The intervention leads to lower overall Chronic GVHD (up to 36 months) (high certainty).
1 finding from 1 review
Intervention not reported
Incidence of relapse (up to 36 months) · patients after allogeneic stem cell or bone marrow transplantation
The intervention showed no clear difference in incidence of relapse (up to 36 months) (moderate certainty).
1 finding from 1 review
Intervention not reported
Non‐relapse mortality (at 36 months) · patients after allogeneic stem cell or bone marrow transplantation
The intervention showed no clear difference in non‐relapse mortality (at 36 months) (moderate certainty).
1 finding from 1 review
Intervention not reported
Graft failure (during study) · patients after allogeneic stem cell or bone marrow transplantation
The intervention showed no clear difference in graft failure (during study) (low certainty).
1 finding from 1 review
Intervention not reported
Adverse Events (during study) · patients after allogeneic stem cell or bone marrow transplantation
1 finding from 1 review
Number of participants with at least 1 bleeding episode · People with chronic bone marrow failure
Thrombopoietin mimetic showed no clear difference in number of participants with at least one bleeding episode compared with placebo (low certainty).
1 finding from 1 review
Number of participants with severe or life‐threatening bleeding · People with chronic bone marrow failure
Thrombopoietin mimetic showed no clear difference in number of participants with at least one severe or life‐threatening… compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · People with chronic bone marrow failure
It is very uncertain whether thrombopoietin mimetic changes all‐cause mortality compared with placebo (very low certainty).
1 finding from 1 review
Proportion of patients receiving platelets · People with chronic bone marrow failure
Thrombopoietin mimetic probably leads to lower proportion of participants receiving a platelet transfusion compared with placebo (moderate certainty).
1 finding from 1 review
Blood transfusion reaction · People with chronic bone marrow failure
1 finding from 1 review
Thromboembolism · People with chronic bone marrow failure
It is very uncertain whether thrombopoietin mimetic changes thromboembolism compared with placebo (very low certainty).
1 finding from 1 review
Adverse drug reactions · People with chronic bone marrow failure
Thrombopoietin mimetic showed no clear difference in drug reactions compared with placebo (low certainty).
1 finding from 1 review
Number of red cell transfusions per participant · People with chronic bone marrow failure
1 finding from 1 review
Mortality attributable to hepatic veno‐occlusive disease ( · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia
Summary of findings: Heparin showed no clear difference in mortality attributable to hepatic veno‐occlusive disease ( compared with no treatment (low certainty).
1 finding from 1 review
Quality of life · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of adverse events ( · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia
It is very uncertain whether summary of findings: Heparin changes frequency of adverse events ( compared with no treatment (very low certainty).
1 finding from 1 review
Incidence of hepatic veno‐occlusive disease ( · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia
It is very uncertain whether summary of findings: Heparin changes incidence of hepatic veno‐occlusive disease ( compared with no treatment (very low certainty).
1 finding from 1 review
Overall survival ( · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia
It is very uncertain whether summary of findings: Heparin changes overall survival ( compared with no treatment (very low certainty).
1 finding from 1 review